Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
11. Dezember 2024 06:00 ET
|
Relay Therapeutics, Inc.
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase...
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
09. Dezember 2024 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
03. Dezember 2024 08:00 ET
|
Relay Therapeutics, Inc.
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown...
Relay Therapeutics to Participate in Upcoming Investor Conferences
07. November 2024 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
06. November 2024 16:05 ET
|
Relay Therapeutics, Inc.
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D Plan to initiate 2L pivotal trial of...
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
30. Oktober 2024 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
10. September 2024 20:21 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Announces Proposed Public Offering of Common Stock
09. September 2024 16:34 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
09. September 2024 06:55 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
06. September 2024 16:05 ET
|
Relay Therapeutics, Inc.
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024